Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Heart disease risk greater for women with a common condition they may not be aware they have - 2'A prank': Israel Police detain suspect for shooting rubber bullets at Ashkelon kindergarten
- 3Figure out How to Score Huge with Open Record Rewards
- 4‘More should be done’: UN pushes Syrian regime on justice for Druze, Alawites and minority groups
- 5Dominating the Art of Composing: Creator Bits of knowledge
- German foreign minister backs abandoning EU's unanimity principle
- The Quadrantid meteor shower peaks tonight, but will the full 'Wolf Moon' outshine the show?
- Must-See Attractions in Australia
- Haifa refinery said hit in latest Iranian missile barrage
- 5 Morning Schedules That Stimulate Your Day
- Parents who delay baby's first vaccines also likely to skip measles shots
- Extraordinary Picks for Home Apparatuses: Making Life Simpler
- From Fledgling to Master: Self-awareness in a Side interest
- Step by step instructions to Pick A Keep money with High Fixed Store Loan costs
